7 recalls found for Zydus Pharmaceuticals (USA) Inc.. Check if any of your products are affected.
Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.
Zydus Pharmaceuticals recalled 600 bottles of Entecavir Tablets on September 24, 2025. The recall follows a failed impurity specification that poses health risks. Consumers should stop using the product immediately and contact healthcare providers for guidance.
Zydus Pharmaceuticals recalled 912 bottles of Entecavir Tablets on September 24, 2025, due to failed impurity specifications. The recall affects 30-count bottles of 0.5 mg tablets Distributed nationwide in the USA.
Zydus Pharmaceuticals recalled 4,344 bottles of Entecavir Tablets on September 4, 2025. The recall stems from failed impurity and degradation specifications. Consumers should stop using the product immediately.
Zydus Pharmaceuticals recalled 4,440 bottles of Entecavir Tablets on September 4, 2025. The recall follows failure to meet impurity and degradation specifications. Consumers should stop using the affected tablets immediately and contact their healthcare provider.
Zydus Pharmaceuticals recalled Chlorpromazine Hydrochloride Tablets on September 3, 2025. The recall affects 100-count bottles of 50 mg tablets due to excessive levels of N-Nitroso Desmethyl Chlorpromazine. Consumers should stop using the product immediately and contact health providers for guidance.
Zydus Pharmaceuticals recalled 270,125 vials of Succinylcholine Chloride Injection on August 27, 2025. The recall follows failed impurity tests indicating unknown degradation issues. Consumers and healthcare providers must stop using the product immediately and seek guidance.